目的:通过检测LEASO患者血清中sVCAM-1的表达水平探讨sVACM-1在LEASO中的临床诊断价值。方法:纳入82例自2023年12月至2024年7月在青岛市市立医院就诊并确诊为LEASO的患者(将其定义为下肢动脉硬化闭塞症组(LEASO组),并根据病变部位及Font...目的:通过检测LEASO患者血清中sVCAM-1的表达水平探讨sVACM-1在LEASO中的临床诊断价值。方法:纳入82例自2023年12月至2024年7月在青岛市市立医院就诊并确诊为LEASO的患者(将其定义为下肢动脉硬化闭塞症组(LEASO组),并根据病变部位及Fontaine分期将其分组。随机纳入同期40名来我院体检的健康者,定义为健康对照组。用酶联免疫吸附法(ELISA)检测各组患者血清sVCAM-1的表达量,计算各组间sVCAM-1表达水平差异;将sVCAM-1与实验室检查结果进行LEASO的影响因素logistic回归分析;并用sVCAM-1联合实验室检查指标对LEASO进行诊断预测。结果:LEASO患者组sVCAM-1表达量高于健康对照组(P 0.05)。而在根据病变涉及的下肢血管部位的分组中,膝上动脉病变组sVCAM-1的表达量最高,且膝上膝下动脉病变合并组sVCAM-1的表达量高于膝下动脉病变组(P Objective: To explore the clinical diagnostic value of sVACM-1 in LEASO by detecting the expression level of sVCAM-1 in serum of LEASO patients. Methods: Eighty-two patients who visited Qingdao Municipal Hospital from December 2023 to July 2024 and were diagnosed with LEASO (defined as the lower extremity atherosclerotic occlusive disease group (LEASO group)) were included and grouped according to the lesion site and Fontaine staging. Forty healthy individuals who came to our hospital for physical examination during the same period were randomly included and defined as the healthy control group. The expression of serum sVCAM-1 was detected by enzyme-linked immunosorbent assay (ELISA) in each group of patients, and the difference of sVCAM-1 expression level between the groups was calculated;logistic regression analysis of the influencing factors of LEASO was carried out by combining sVCAM-1 with the laboratory examination results;and diagnostic prediction of LEASO was carried out by using sVCAM-1 in combination with laboratory examination indexes. Results: The expression of sVCAM-1 in the LEASO patient group was higher than that in the healthy control group (P 0.05). In contrast, in the grouping according to the vascular site of the lower limb involved in the lesion, the expression of sVCAM-1 was highest in the supra-knee artery lesion group, and the expression of sVCAM-1 in the combined supra-knee infra-knee artery lesion group was higher than that of the infra-knee artery lesion group (P < 0.05). sVCAM-1 expression was also progressively higher with the elevation of Fontaine’s stage in the LEASO group, but the expression of Fontaine stage IV sVCAM-1 expression decreased compared with stage III. The results of logistic regression analysis of the influencing factors showed that TC (OR = 2.222, 95%CI: 1.323~3.730), LDL-C (OR = 1.802, 95%CI: 1.232~2.637), and sVCAM-1 (OR = 1.003, 95%CI: 1.001~1.005) were the independent risk factors. Finally, sVCAM-1 was combined with meaningful laboratory indicators for the diagnostic prediction of LEASO using the subject’s working curve, and the ROC curve was sensitive. Conclusion: sVCAM-1 may be involved in the occurrence and development of LEASO, and by detecting the expression of serum sVCAM-1, it may provide new ideas and methods for the diagnosis and treatment of LEASO.展开更多
目的:检索并总结下肢动脉硬化闭塞症伴间歇性跛行病人运动疗法的相关证据,为下肢动脉硬化闭塞症伴间歇性跛行病人进行运动锻炼提供参考。方法:根据“6S”金字塔证据模型,系统检索BMJ Best Practice、UpToDate、the Cochrane Library、...目的:检索并总结下肢动脉硬化闭塞症伴间歇性跛行病人运动疗法的相关证据,为下肢动脉硬化闭塞症伴间歇性跛行病人进行运动锻炼提供参考。方法:根据“6S”金字塔证据模型,系统检索BMJ Best Practice、UpToDate、the Cochrane Library、澳大利亚Joanna Briggs Institute(JBI)循证卫生保健中心、英国国家卫生和临床优化研究所(NICE)、苏格兰校际指南网(SIGN)、美国国立指南库(NGC)、医脉通、美国血管外科协会、美国心脏病学会(ACC)、美国心脏协会(AHA)、欧洲心脏协会、PubMed、CINANL、MedLine、Web of Science、中国生物医学文献数据库、中国知网、万方数据库和维普数据库公开发表的下肢动脉硬化闭塞症伴间歇性跛行病人运动疗法的相关文献,包括临床实践指南、专家共识、证据总结、系统评价和Meta分析,检索时限从2017年10月—2023年10月。经过质量评价并结合专业判断,对纳入的文献进行证据的提取和汇总。结果:共纳入25篇文献,包括2篇临床实践指南、4篇证据总结、1篇专家共识、18篇系统评价,最终从运动的适用对象、运动的评估/培训、运动地点、运动流程、运动类型/方式、运动时间/频次/周期、运动强度、运动时的质量控制、运动的效果评价、运动时的注意事项10个方面形成下肢动脉硬化闭塞症伴间歇性跛行病人运动疗法的最佳证据。结论:本研究总结了下肢动脉硬化闭塞症伴间歇性跛行病人运动疗法的最佳证据,为制定下肢动脉硬化闭塞症伴间歇性跛行病人的运动方案提供证据支持。展开更多
文摘目的:通过检测LEASO患者血清中sVCAM-1的表达水平探讨sVACM-1在LEASO中的临床诊断价值。方法:纳入82例自2023年12月至2024年7月在青岛市市立医院就诊并确诊为LEASO的患者(将其定义为下肢动脉硬化闭塞症组(LEASO组),并根据病变部位及Fontaine分期将其分组。随机纳入同期40名来我院体检的健康者,定义为健康对照组。用酶联免疫吸附法(ELISA)检测各组患者血清sVCAM-1的表达量,计算各组间sVCAM-1表达水平差异;将sVCAM-1与实验室检查结果进行LEASO的影响因素logistic回归分析;并用sVCAM-1联合实验室检查指标对LEASO进行诊断预测。结果:LEASO患者组sVCAM-1表达量高于健康对照组(P 0.05)。而在根据病变涉及的下肢血管部位的分组中,膝上动脉病变组sVCAM-1的表达量最高,且膝上膝下动脉病变合并组sVCAM-1的表达量高于膝下动脉病变组(P Objective: To explore the clinical diagnostic value of sVACM-1 in LEASO by detecting the expression level of sVCAM-1 in serum of LEASO patients. Methods: Eighty-two patients who visited Qingdao Municipal Hospital from December 2023 to July 2024 and were diagnosed with LEASO (defined as the lower extremity atherosclerotic occlusive disease group (LEASO group)) were included and grouped according to the lesion site and Fontaine staging. Forty healthy individuals who came to our hospital for physical examination during the same period were randomly included and defined as the healthy control group. The expression of serum sVCAM-1 was detected by enzyme-linked immunosorbent assay (ELISA) in each group of patients, and the difference of sVCAM-1 expression level between the groups was calculated;logistic regression analysis of the influencing factors of LEASO was carried out by combining sVCAM-1 with the laboratory examination results;and diagnostic prediction of LEASO was carried out by using sVCAM-1 in combination with laboratory examination indexes. Results: The expression of sVCAM-1 in the LEASO patient group was higher than that in the healthy control group (P 0.05). In contrast, in the grouping according to the vascular site of the lower limb involved in the lesion, the expression of sVCAM-1 was highest in the supra-knee artery lesion group, and the expression of sVCAM-1 in the combined supra-knee infra-knee artery lesion group was higher than that of the infra-knee artery lesion group (P < 0.05). sVCAM-1 expression was also progressively higher with the elevation of Fontaine’s stage in the LEASO group, but the expression of Fontaine stage IV sVCAM-1 expression decreased compared with stage III. The results of logistic regression analysis of the influencing factors showed that TC (OR = 2.222, 95%CI: 1.323~3.730), LDL-C (OR = 1.802, 95%CI: 1.232~2.637), and sVCAM-1 (OR = 1.003, 95%CI: 1.001~1.005) were the independent risk factors. Finally, sVCAM-1 was combined with meaningful laboratory indicators for the diagnostic prediction of LEASO using the subject’s working curve, and the ROC curve was sensitive. Conclusion: sVCAM-1 may be involved in the occurrence and development of LEASO, and by detecting the expression of serum sVCAM-1, it may provide new ideas and methods for the diagnosis and treatment of LEASO.
文摘目的:检索并总结下肢动脉硬化闭塞症伴间歇性跛行病人运动疗法的相关证据,为下肢动脉硬化闭塞症伴间歇性跛行病人进行运动锻炼提供参考。方法:根据“6S”金字塔证据模型,系统检索BMJ Best Practice、UpToDate、the Cochrane Library、澳大利亚Joanna Briggs Institute(JBI)循证卫生保健中心、英国国家卫生和临床优化研究所(NICE)、苏格兰校际指南网(SIGN)、美国国立指南库(NGC)、医脉通、美国血管外科协会、美国心脏病学会(ACC)、美国心脏协会(AHA)、欧洲心脏协会、PubMed、CINANL、MedLine、Web of Science、中国生物医学文献数据库、中国知网、万方数据库和维普数据库公开发表的下肢动脉硬化闭塞症伴间歇性跛行病人运动疗法的相关文献,包括临床实践指南、专家共识、证据总结、系统评价和Meta分析,检索时限从2017年10月—2023年10月。经过质量评价并结合专业判断,对纳入的文献进行证据的提取和汇总。结果:共纳入25篇文献,包括2篇临床实践指南、4篇证据总结、1篇专家共识、18篇系统评价,最终从运动的适用对象、运动的评估/培训、运动地点、运动流程、运动类型/方式、运动时间/频次/周期、运动强度、运动时的质量控制、运动的效果评价、运动时的注意事项10个方面形成下肢动脉硬化闭塞症伴间歇性跛行病人运动疗法的最佳证据。结论:本研究总结了下肢动脉硬化闭塞症伴间歇性跛行病人运动疗法的最佳证据,为制定下肢动脉硬化闭塞症伴间歇性跛行病人的运动方案提供证据支持。
